Please wait...

Maximize the utility of
imaging biomarkers
to the benefit of
patients with arthritis.
Learn more about the project  

AutoPiX is a major international project focused on improving healthcare for people with rheumatic and musculoskeletal diseases (RMDs).

The AutoPiX project brings together pharmaceutical and medical technology partners with leading academic institutions to enhance the use of imaging biomarkers for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), collectively known as systemic arthritides.

It aims to develop advanced imaging tools and artificial intelligence (AI) models to better diagnose, monitor, and treat these conditions. These tools will make use of imaging biomarkers—like X-rays, ultrasounds, and MRIs—to provide more precise and personalised care.

AutoPiX is a major international project focused on improving healthcare for people with rheumatic and musculoskeletal diseases (RMDs).

The AutoPiX project brings together pharmaceutical and medical technology partners with leading academic institutions to enhance the use of imaging biomarkers for patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA), collectively known as systemic arthritides.

It aims to develop advanced imaging tools and artificial intelligence (AI) models to better diagnose, monitor, and treat these conditions. These tools will make use of imaging biomarkers—like X-rays, ultrasounds, and MRIs—to provide more precise and personalised care.

Learn more about the project  

INMUSC – Instituto de Salud Musculoesquelética, SL

Inmusc is a SME that provides research consultancy in Spain. Inmusc works with various types of clients interested in advancing knowledge, both in the execution of research projects and in training programs in methodology. We establish contracts, collaboration agreements, and other formulas facilitating agile and relevant research co-development.

What is the role of INMUSC in Autopix

In AutoPiX, Inmusc will coordinate WP8, i.e., Inmusc will ensure effective communication, stakeholder engagement, and regulatory compliance to maximise the project’s impact.

Q&A

In what part of the patient journey will your institution most likely contribute?

Most likely we will impact in all the phases of the patient journey as we, in Inmusc, are dedicated to the communication, exploitation, and dissemination of results. So our role will actually make sure that impact reaches the stakeholders that we are aiming for.

What long-term impacts do you envision of your contribution?

We hope the messages we send from AutoPiX, and for which Inmusc is the main contributor, really reflect and are able and powerful to make it in the long term. So we will make the connections with the most influential stakeholders, we will send the most powerful messages and hopefully that will stay for the long term, we really want to make a change.

Why is it so important?

Our contribution from the communication perspective is critical for AutoPiX. It is a very complex and technological project that might not reach the public well if it’s not explained properly. The team in Inmusc is devoted to translating the findings and the results and all the innovations that AutoPiX produces into terms that are understandable, and are easy to bring to practice, easy to understand by the rheumatologists, the patients, and the ones that will be implementing those things in the daily life. So it’s critical that we express ourselves very clearly.

Team picture of Instituto de Salud Musculoesquelética, SL

Contact

Loreto Carmona
Scientific Director
Estíbaliz Loza (Esti)
Medical Director
Esther Martín-Blas
Manager (Legal and Finances)
María Jesús García de Yébenes
Researcher
Teresa Otón
Researcher
Concepción Cantalapiedra (Concha)
Research Assistant